Shakun Malik

Shakun Malik

UNVERIFIED PROFILE

Are you Shakun Malik?   Register this Author

Register author
Shakun Malik

Shakun Malik

Publications by authors named "Shakun Malik"

Are you Shakun Malik?   Register this Author

29Publications

1027Reads

8Profile Views

Disease Labels and Clear Communication With Patients-A Rose by Any Other Name Would Smell as Sweet.

JAMA Oncol 2019 06;5(6):784-785

Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaoncol.2019.0053DOI Listing
June 2019

Current Treatment Landscape of Nasopharyngeal Carcinoma and Potential Trials Evaluating the Value of Immunotherapy.

J Natl Cancer Inst 2019 03 26. Epub 2019 Mar 26.

Clinical Investigative Branch, Cancer Therapy Evaluation Program, National Institute of Health, Bethesda, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djz044DOI Listing
March 2019

Steps forward for cancer precision medicine.

Nat Rev Drug Discov 2018 01 24;17(1):1-2. Epub 2017 Nov 24.

EORTC Headquarters, 1200 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrd.2017.218DOI Listing
January 2018

Societal challenges of precision medicine: Bringing order to chaos.

Eur J Cancer 2017 10 4;84:325-334. Epub 2017 Sep 4.

EORTC Headquarters, Brussels, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.07.028DOI Listing
October 2017

Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe.

Clin Lung Cancer 2017 01 27;18(1):5-12. Epub 2016 Jun 27.

Hematology and Medical Oncology, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2016.06.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5361177PMC
January 2017

Small Cell Lung Cancer Screen of Oncology Drugs, Investigational Agents, and Gene and microRNA Expression.

J Natl Cancer Inst 2016 10 31;108(10). Epub 2016 May 31.

Affiliations of authors: Molecular Pharmacology Group, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD (DE, TS, RD, JL, CO, RR, MS, JC, EH, NF, AM); Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis (MK, GK, JM, BAT), Biometric Research Program, Division of Cancer Treatment and Diagnosis (EP, DS), and Cancer Therapy Evaluation Program (SM), National Cancer Institute, Rockville, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djw122DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6279282PMC
October 2016

National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network.

Am Soc Clin Oncol Educ Book 2014 :71-6

From the Division of Cancer Treatment and Diagnosis, National Cancer Institute at the National Institutes of Health, Bethesda, MD; Center for Cancer Genomics, National Cancer Institute at the National Institutes of Health, Bethesda, MD; and Leidos Corporation, Frederick, MD.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2014.34.71DOI Listing
November 2015

Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer.

J Thorac Oncol 2014 Oct;9(10):1443-8

*Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; †Offices of Hematology and Oncology Products, Center for Drug Evaluation and Research U.S. Food and Drug Administration, Silver Spring, MD; ‡University of Pittsburgh Medical Center, Pittsburgh, PA; §University of Utah, Salt Lake City, UT; ‖Duke University Medical Center, Durham, NC; ¶Biometric Research Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda, MD; and #University of Colorado, School of Medicine, Denver, CO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000314DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4165474PMC
October 2014

U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.

Clin Cancer Res 2014 Apr 26;20(8):2029-34. Epub 2014 Feb 26.

Authors' Affiliations: Clinical Investigations Branch, Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health, Bethesda; Offices of Hematology and Oncology Products, Biostatistics, and Clinical Pharmacology, Center for Drug Evaluation and Research; and Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiologic Health; U.S. Food and Drug Administration, Silver Spring, Maryland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-13-3077DOI Listing
April 2014

Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancer.

J Thorac Oncol 2014 Jan;9(1):121-5

*H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida; †Arlington Cancer Center, Arlington, Texas; ‡Mayo Clinic Arizona, Scottsdale, Arizona; §Georgetown University Hospital, Washington, District of Columbia; ‖University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland; ¶Tower Cancer Research Foundation, Beverly Hills, California; #MedStar Research Institute, Hyattsville, Maryland; and **formerly Gemin X Pharmaceuticals, an indirect wholly owned subsidiary of Teva Pharmaceutical Industries Ltd., Petach Tikva, Israel.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/JTO.0000000000000027DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4666503PMC
January 2014

A phase I trial of bexarotene in combination with docetaxel in patients with advanced solid tumors.

Clin Lung Cancer 2011 Jul 24;12(4):231-6. Epub 2011 Apr 24.

FDA, Office of Oncology Drug Products, Silver Spring, MD, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cllc.2011.03.024DOI Listing
July 2011

HIV-related large B-cell lymphoma confined to the bone marrow with a fulminant clinical course: a case report and literature review.

Clin Adv Hematol Oncol 2007 Aug;5(8):622-4; discussion 625-6

Lombardi Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA.

View Article

Download full-text PDF

Source
August 2007

A phase II trial of ISIS 3521 in patients with metastatic colorectal cancer.

Clin Colorectal Cancer 2004 Nov;4(4):268-74

Vincent T. Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC 20007, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/ccc.2004.n.026DOI Listing
November 2004

The impact of aging on chemotherapy.

Authors:
Shakun M Malik

Clin Lung Cancer 2004 Jan;5(4):243-4

Lombardi Cancer Center Georgetown University Washington, DC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1525-7304(11)70345-XDOI Listing
January 2004